The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Jivi Market Change Between 2026 And 2030?
Historically, growth was spurred by the frequent bleeding episodes experienced in hemophilia A, the limitations inherent in standard factor VIII therapies, and the prompt adoption of early recombinant factor treatments. Additionally, a strong emphasis on preventing joint damage and an expansion in hemophilia treatment centers also contributed to this development.
Anticipated expansion during the forecast period is driven by the growing utilization of long-acting clotting factors, enhanced accessibility to home infusion services, the broadening of pediatric hemophilia care, advantageous reimbursement frameworks, and pioneering advancements in recombinant therapies. Key developments expected within this period encompass the increasing integration of extended half-life factor VIII, a transition towards preventative hemophilia management strategies, a preference for less frequent injections, the expansion of home-centric hemophilia care solutions, and better patient compliance with treatment regimens.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20117&type=smp
What Core Drivers Are Transforming The Jivi Market?
The growing incidence of hemophilia is projected to drive the expansion of the jivi market in the future. Hemophilia arises from genetic mutations in X-linked genes crucial for producing clotting factors, resulting in inadequate or faulty clotting factors VIII (hemophilia A) or IX (hemophilia B), which hinder the blood’s capacity to clot effectively. The prevalence of hemophilia is on the rise globally due to enhanced diagnostic capabilities, greater public awareness, and increased reporting of cases. Jivi assists hemophilia patients by replacing the missing Factor VIII with a long-acting recombinant therapy, thereby aiding blood clotting to prevent or manage bleeding episodes. Its extended half-life also means less frequent dosing, improving patient convenience and compliance. For example, in April 2025, as reported by Hemophilia News Today, a US-based medical news platform, the global count of individuals living with hemophilia was estimated at approximately 836,000, which included about 284,000 people suffering from the severe form of the condition. Consequently, the increasing prevalence of hemophilia is fostering the growth of the jivi market. An increasing emphasis on personalized medicine is anticipated to stimulate the growth of the jivi market moving forward. Personalized medicine represents a healthcare strategy that customizes treatments and therapies based on an individual’s genetic composition, environment, and lifestyle. Several elements contribute to the demand for personalized medicine, such as breakthroughs in genomic medicine, a rise in chronic diseases, advanced diagnostic tools, and a patient-centric approach to healthcare. Jivi functions as a form of personalized medicine by providing customized treatment for hemophilia A patients; its extended half-life enables tailored dosing schedules that align with individual patient needs, thereby improving adherence and reducing bleeding episodes. For instance, in February 2024, data from the Personalized Medicine Coalition, a US-based hospital and healthcare organization, indicated that in 2023, the FDA sanctioned 16 new personalized treatments for patients with rare diseases, a notable increase from six in 2022. Thus, the heightened focus on personalized medicine is propelling the growth of the jivi market.
How Is The Jivi Market Examined Through Segment Analysis?
The jivi market covered in this report is segmented –
1) By Formulation: Lyophilized Powder For Reconstitution, Ready-to-use Formulations
2) By Route of Administration: Intravenous, Subcutaneous
3) By Indication: Treatment Of Hemophilia A, Prophylaxis, On-demand Treatment For Bleeding Episodes
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies
5) By End Use: Hospitals, Hemophilia Treatment Centres, Specialty Clinics, Home Healthcare Settings
Which Organizations Are Operating Within The Jivi Market?
Major companies operating in the jivi market are Bayer AG
Access The Complete Jivi Market Report:
https://www.thebusinessresearchcompany.com/report/jivi-global-market-report
Which Region Stands As The Largest Contributor To The Jivi Market?
North America was the largest region in the jivi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the jivi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model